SUNPHARMANSESun Pharmaceutical Industries Limited· PharmaceuticalsMediumNeutral
Announced Sat, 4 Apr · 16:00 IST

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Appointment of Independent Director

Director Flagged GovernanceManagement Changes View source PDF

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.7%1-day move
₹1692.00
prior close
₹1684.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.9-1.0-1.6+1.7+1.2+1.4-2.2-2.3+0.2+3.4+9.3+5.9+13.1
Up moveDown movePending
AI summary

Sun Pharma's Board has approved the appointment of Ms. Satyavati Berera as an Independent Director for a term of 5 years, subject to shareholder approval via postal ballot. Ms. Berera is a former Chief Operating Officer of PwC India with over 40 years of experience in Assurance, Consulting, and Governance Risk and Compliance services. She brings expertise in Finance, Operations, Human Capital, Technology, and Regulatory compliance. The company states she is not related to any Director, Key Managerial Personnel, or promoter. The appointment is intended to reinforce board independence, governance effectiveness, and oversight capabilities while maintaining compliance with Companies Act 2013 and SEBI LODR requirements.

Likely market impact

This appointment strengthens Sun Pharma's board governance and independence credentials. The addition of an experienced professional with extensive finance and compliance background is positive for shareholder confidence, though the appointment remains pending shareholder approval.